
Best-selling author Stephen King is slated to testify for the federal government in an antitrust suit aimed to block Penguin Random House’s $2.18 billion acquisition of Simon & Schuster.
King is being called as a witness in federal court in Washington about his experiences as a popular author in selling anticipated top-selling books, according to court filings.
The author of horror classics including “Carrie” and “The Shining” is expected to testify specifically about publishers that successfully purchase rights to anticipated best-sellers and what effects he believes the proposed deal will have on the markets for those books.
Preliminary witness lists were filed over the weekend, with the government intending to call King – who is published by S&S in the US – early in the proceedings to testify about his experiences. He will be asked about his perceptions of how the market for book rights operates, the expectations and needs of top-selling authors, the characteristics of firms that successfully purchase anticipated top-selling titles and the likely effects of the proposed transaction on the market for anticipated bestsellers.
Other notable figures who could provide testimony include Hachette Book Group US c.e.o. Michael Pietsch, S&S president and c.e.o. Jonathan Karp, PRH chairman and c.e.o. Markus Dohle and Macmillan c.e.o. Don Weisberg. Karp and Dohle are expected to testify about the competition between PRH and S&S for anticipated top-selling books.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas